Publikationen

Fachzeitschriften (Auswahl)

  • Wolf E, Jaeger H. The Concept of the New ERA Study. MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:24-6. German.
  • Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C. HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis. 2013 Oct;45(10):766-72.
  • Dinkel A, Nather C, Jaeger H, Jaegel-Guedes E, Lahmann C, Steinke C, Wolf E, Ronel J. Stigmatization in HIV/AIDS: first German adaptation of the HIV-stigma scale (HSS-D). Psychother Psychosom Med Psychol. 2014 Jan;64(1):20-7. doi: 10.1055/s-0033-1341449. Epub 2013 May 15. German.
  • Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, Mayr C, Jaeger H, Pfaff H, Dupke S, Neumann A. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ. 2013 Oct;14(5):799-808. doi: 10.1007/s10198-012-0425-4. Epub 2012 Sep 19.
  • Obermeier M, Pironti A, Berg T, Braun P, Däumer M, Eberle J, Ehret R, Kaiser R, Kleinkauf N, Korn K, Kücherer C, Müller H, Noah C, Stürmer M, Thielen A, Wolf E, Walter H. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology. 2012;55(2):102-7.
  • Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study. Eur J Health Econ 2012.
  • Obermeier M, Ehret R, Berg T, Braun P, Korn K, Muller H, Noah C, Stürmer M, Thielen A, Walter H, Wolf E, Kaiser R. Genotypic HIV-coreceptor tropism prediction with geno2pheno [coreceptor]: differences depending on HIV-1-subtype. J Int AIDS Soc 2012; 15(6):18214.Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. Eur J Med Res. 2011 Mar 28;16(3):93-100.
  • Glaubitz J, Sizmann D, Simon CO, Hoffmann KS, Drogan D, Hesse M, et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011; 50(2):119-124.
  • Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; Competence Network for HIV/AIDS. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011; 39(1):3-12.
  • Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, et al. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr 2011; 56(2):109-117.
  • Jaeger H, Wolf E, Simon CO, Babiel R. Traceability of 3 generations of nucleic acid amplification tests for quantitative HIV-1 RNA measurements to meet the WHO HIV-1 RNA International Standards. J Acquir Immune Defic Syndr 2010; 54(3):334-335.
  • Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, et al. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res 2010; 15(4):145-151.
  • Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, et al. Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naive or pretreated but protease inhibitor-naive HIV-positive patients. Infection 2010; 38(2):108-116.
  • Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, et al. Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2010; 54(1):51-58.
  • Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009; 14(7):277-283.
  • Kastenbauer U, Wolf E, Kollan C, Hamouda O, Bogner JR. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease. Eur J Med Res 2009; 14(6):244-249.
  • Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther 2008; 13(8):1091-1095.
  • Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8(5):679-688.
  • Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect 2007; 13(5):510-515.
  • Hoffmann C, Stellbrink HJ, Dielschneider T, Degen O, Stoehr A, Knechten H, et al. Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis. Br J Haematol 2007; 136(4):641-648.
  • Hoffmann C, Wolf E, Wyen C, Fatkenheuer G, van LJ, Stellbrink HJ, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2006; 47(9):1872-1880.
  • Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von BF, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20(15):1951-1954.
  • Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H. [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr 2006; 131(34-35):1849-1852.
  • Fehr JS, Nicca D, Sendi P, Wolf E, Wagels T, Kiss A, et al. Starting or changing therapy – a prospective study exploring antiretroviral decision-making. Infection 2005; 33(4):249-256.
  • Wolf E, Hoffmann C, Procaccianti M, Mosthaf F, Gersbacher E, Ulmer A, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res 2005; 10(2):56-62.
  • Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van LJ, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 2004; 125(4):455-462.
  • Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5(1):15-17.
  • Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17(10):1521-1529.
  • Mauss S, Wolf E, Hans J. Changing incidence of mycobacterial diseases in German patients with HIV infection. AIDS Read 1999; 9(6):386, 391-386, 392.
  • Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3(1):49-55.
  • Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15(16):2119-2127.

Abstracts/Posterpräsentationen. Nationale und internationale Fachkongresse (Auswahl)

  • Wolf E, Bogner J, Schewe K, Avettand-Fènoël V, Koegl C, Pauli R, Brust J, Ulmer A, Schneider L, and Jaeger H. How to Characterize Post-Treatment Controllers in Patients Treated During Primary HIV Infection? Conference on Retroviruses and Opportunistic Infections. Boston, USA. 03.-06. March 2014. Abstract P394
  • Koegl C, Wolf E, Balogh A, Mueck B, Jaeger H. Erfassung der Prävalenz von neuropathischen Schmerzen bei HIV+ Patienten mittels des painDETECT Schmerzfragebogens. 6. Deutsch-Österreichischer AIDS-Kongress. Innsbruck, Österreich. 12.-15. Juni 2013. Abstract-ID 140/oral
  • Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Koeppe S, Lutz T, Mueller M, Schmidt W, Trein A, van Wyk J, Koenig B and Stellbrink H. Treatment response to LPV/r-based HAART in HIV-infected patients aged >60 years – data from the STAR/STELLA cohorts. 11th International Congress on Drug Therapy in HIV Infection Glasgow, UK. 11. – 15. November 2012. Abstract P319. Journal of the International AIDS Society, Vol 15 Supplement 4 (2012)
  • Koegl C, Wolf E, Brust J, Baumann R, Schlote F, Karwat M, Heiken H, Mosthaf F, Schoelzel S, Wuensche T, Mueck B, Jaeger H and the 50/2010 study group. First alert level for cognitive impairment in one of ten elderly HIV+ patients, but prevalence not significantly different from diabetes mellitus and control patients in the German 50/2010 cohort. XIX International AIDS Conference. Washington, USA. 22. – 27. July 2012. Abstract WePe070
  • Wolf E, Mauss S, Balogh A, Koegl C, Berger F, Schmutz G, Jaegel-Guedes E, Do T, Jaeger H. NNRTI-based regimens and CD8+ cell count ≤750/μl are associated with fewer viral blips in HIV+ patients on suppressive ART. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy. 17.– 20. July 2011. Abstract MoPe064
  • Wolf E, Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Koeppe S, Lutz T, Mueller M, Schmidt W, Trein A, van Wyk J, Trinh R, Koenig B and Stellbrink HJ. Baseline CD4 cell count is not independently associated with virologic response rates in lopinavir/ritonavir treated, ART-naïve patients in the German STAR and STELLA cohorts. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy. 17.– 20. July 2011. Abstract MoPe210
  • Wolf E, Balogh A, Baumann R, Denger R, Schoelzel S, Wuensche T, at al., and the 50/2010 study group. HDL in aging HIV+ patients treated with or without Nevirapine compared to HIV-negative patient groups – Results from the German 50/2010 Cohort Study. Abstract/Poster P-22
  • Koegl C, Wolf E, Trapana G, Schlote F, Gospodinov B, Kuhlmann B, et al., and the 50/2010 study group. HIV+ and diabetes mellitus II not associated with depressive disorders in aging population. Results from the German 50/2010 cohort study. 1st International Workshop on HIV & Aging, Baltimore, MD, USA, 4-5 October 2010. Abstract/PosterP-05
  • Mueck B, Koegl C, Wolf E, Karwat M, Baumgarten A, Rausch M, et al., and the 50/2010 study group. Sexual dysfunction in an aging HIV positive population compared to HIV negative control groups. Results from the German 50/2010 cohort study. 1st International Workshop on HIV & Aging, Baltimore, MD, USA, 4-5 October 2010. Abstract/Oral presentation O-10
  • Wolf E, Eger J, Balogh A, Goelz J, Brust J, Rockstroh J, et al. and the NoVi Study Group. CD4 Slope in HIV Elite and Viremic Controllers – Data from the German NoVi Cohort. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEAA0105, oral presentation
  • Wolf E, Balogh A, Koegl, Baumann R, Denger R, Schoelzel S, et al., and the 50/2010 study group. Excess Cardiovascular Risk in HIV+ Patients Aged over 50 – Results from the German 50/2010 Cohort Study in Aging Populations of HIV+ and HIV- Patients. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEPE0043
  • Koegl C, Wolf E, Mueck B, Schlote F, Gospodinov B, Kuhlmann B, et al., and the 50/2010 study group Depressive Disorders are Associated with Socio-Economic Factors and Not with Chronic Diseases like HIV + or Diabetes Mellitus – Results from the German 50/2010 Cohort Study in Aging Populations of HIV+ and HIV– Patients. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEPE0041
  • Mauss S, Wolf E, Berger F, Koegl C, Hegener P, Schmutz G, Henke J, Jaeger H. Are there clinical consequences of low level viremia after introducing a more sensitive real-time PCR assay? XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract TUPE0110
  • Mueck B, Koegl C, Wolf E, Karwat M, Baumgarten A, Rausch M, et al., and the 50/2010 study group. Is Sexual Dysfunction Associated with HIV Infection or Age? Results from the German 50/2010 Cohort Study in Aging Populations of HIV+ and HIV- Patients. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEPE0044
  • Knechten H, Wiesmann F, Wolf E, Scholten S, Schnaitmann E, Trein A, et al. Clinical outcome of HIV tropism testing and Maraviroc regimens – 48 weeks follow-up. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract THPE0142
  • Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger , Koeppe S, Lutz T, Mueller M, Schmidt W, Trein A, Wolf E, Petry R and Stellbrink HJ. Similar virological response in Art-naïve HIV+ patients with low CD4 cell counts initiating a Lopinavir/Ritonavir-based regimen. 48 week data from the German STAR and STELLA cohorts. 12th European AIDS Conference (EACS), Cologne, Germany, 11 – 14 November 2009. Abstract PE 7.9/20
  • Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Lutz T, Mueller M, Schmidt W, Trein A, Pauli R, Wolf E, Petry R, Stellbrink HJ. Kivexa versus Truvada: Similar virological outcomes in ART-naive patients starting a Lopinavir/Ritonavir-based regimen. 48-week-data from the STAR and STELLA Cohorts. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19 – 22 July 2009. Abstract MOPEB055
  • Wolf E, Braun P, Schneider L, Knechten H, Karwat M, Balogh A, Ehret R, Mosthaf F, Ulmer A, Jaeger H. Predictors for CXCR4-Tropism: CD4-Nadir and the Use of the Enhanced Sensitivity (ES) Trofile Assay. 1. Deutsch-Österreichisch-Schweizerischer AIDS-Kongress – SÖDAK 2009. St. Gallen. Schweiz. 24. – 27. Juni 2009. Abstract P483
  • Wolf E, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Lutz T, Mueller M, Schmidt W, Trein A, Pauli R, Koegl C, Petry R, Stellbrink HJ. Kivexa versus Truvada: Similar virological outcomes in ART-naive patients starting a Lopinavir/Ritonavir-based regimen. 48 week data from the STAR and STELLA Cohorts. 1. Deutsch-Österreichisch-Schweizerischer AIDS-Kongress – SÖDAK 2009. St. Gallen. Schweiz. 24. – 27. Juni 2009. Abstract P415
  • Wolf E, Stoll M, Becker-Andre M,. Bogner J, Becker W, Gorriahn D, Mueller MC, Jaeger H, Welte R, Baudewig M, Walli R. Prospective HLA-B*5701 screening for abacavir hypersensitivity saves costs. XVII International AIDS Conference, Mexico City, Mexico, August 03 – 08, 2008. Abstract THPE0192 (Poster)
  • Stellbrink H-J, Schewe K, Hoffmann C, Wolf E. Is there a harmless level of plasma viremia inuntreated HIV infection? CD4+ T Cells in the long-term follow-up of Elite Controllers and controls. 15th Conference on Retroviruses and Opportunistic Infections. Boston. 3.-6. Februar 2008. Abstract 351 (Poster)
  • Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, and the Prime-DAG and Ac-DAG Study Group. No Benefit from Early Treatment in Primary HIV-Infection? 14th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles. 25.- 28. February 2007. Late Breaker 125 (oral presentation)
  • Wolf E, Koegl C, Theobald T, Jaegel-Guedes E, Jaeger H. Nevirapine-associated hepatotoxicity: no increased risk for females or high CD4 count in a single-centre HIV cohort. 46th annual ICAAC. San Francisco. 27.-30. September 2006. Abstract H-1063 (oral presentation)
  • Wolf E, Gunturu G, Koegl C, Jaegel-Guedes E, Jaeger H. Tenofovir (TDF) versus non-TDF-containing ART: renal safety in daily practice. Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Abstract P153 (Poster)
  • Jaeger H, Wolf E, Jaegel-Guedes E, Chantratita W, Schumacher W. HIV real-time PCR assay COBAS AmpliPrep/COBAS TaqMan HIV-1 test in comparison to the Bayer bDNA assay versant HIV-1 RNA v3.0 and the Roche COBAS amplicor HIV monitor test v1.5. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract MOPE0156 (Poster)
  • Wolf E, Walter H, Eckerlein B, Koegl C, Jaegel-Guedes E, Jaeger H. Development of De Novo PI-Resistance in Lopinavir/ Ritonavir-Monotherapy. 3rd IAS Conference on Pathogenesis and Treatment. Rio de Janeiro. 24.-27. Juli 2005. Abstract WePe4.4C08 (Poster)
  • v. Krosigk A, Meyer T, Stoehr A, Jaegel-Guedes E, Jaeger H, Plettenberg A. Lymphograuloma venerum in HIV/AIDS: Increase in an often misdiagnosed disease. 10. Deutscher und 16. Österreichischer AIDS-Kongress. Wien. 1.-4. Juni 2005. Abstract V42 (oral presentation)